A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
about
Evolution of management in peritoneal surface malignanciesAdhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic optionsRole of multi-modality therapy in peritoneal carcinomatosis and visceral metastasis: a case report and review of the literatureAddition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroupsColonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature reviewTargeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available dataCancer, physical activity, and exerciseEfficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trialsThe efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials.The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials.Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study.Comparative effectiveness of anti-VEGF agents for diabetic macular edema.Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-dateVenous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer.Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal CancerMicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trialIncidence of new-onset hypertension in cancer patients: a retrospective cohort study.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey.Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis.Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling.The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis.Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer
P2860
Q26741293-C34A3BF8-BD60-4508-B97B-9479262CF2AEQ26748666-B717917E-2DBC-4B2F-9AFC-587BC685C2E0Q26799152-D5CF052D-BB99-41EF-9BF4-86760EF973A1Q26822395-76DD814A-E519-40EA-8BA1-A7F7F421CB79Q27014015-E7C81556-EE03-4B6A-B6E9-02ED01725E07Q30862367-8321160F-F6FE-475A-ADEB-140D432475FCQ34004946-EFE3C6A6-365A-424A-BA92-5BCBADB038D1Q34654605-FA3A8BA2-F14F-4D77-B00D-50D0290A2408Q34685531-CF230BCB-5363-45F5-B4E2-10F0E31AB014Q34773758-CB27991E-4475-4139-ABF3-6335C391B238Q34996343-F7154E07-4D58-4271-8874-8C2D89E23B4DQ35056819-F74B8D2B-8489-427D-AF91-EC880E7FA4BFQ35173951-0ED7425D-D1CA-4191-8CDF-388903CEDCBFQ36166850-12613103-F506-40EE-8FC3-8512D3D39229Q36286831-F2B41FAE-E99D-4BCE-8694-4C29A1011F1FQ36706378-2D5C34A0-0E48-4585-BBFD-FEFE1BE8BEC8Q36762304-7D287FD0-556E-4E69-947C-03D413D5A34CQ37185814-592C829C-6EBE-465F-A8BA-6B1FA1571A62Q37422797-40DBB864-FB81-4214-9D6F-FAB5034BC2A4Q37632167-9D050D81-E044-4436-9246-166F362EDEA5Q37669073-27F724AE-C4C8-4D00-BF51-2BE89F708CAFQ37961087-5AC215BC-6999-449B-87E6-83882CE5BA20Q38234000-B233818E-AD6F-4BBD-917C-2F064F2DF366Q38371293-48BE8313-1C08-47C2-AD21-727A981037B6Q40975248-5447FE0D-088D-45AC-BE7C-76D86D9ABEAAQ42682716-5BC9FDAE-DEEF-4E80-A520-C84DE9CBC045Q43834221-700F3180-F458-4EFD-8840-4C956E01A585Q44029291-C6036639-8591-4BC1-A600-565A4E196888Q49965720-E6294E7E-B24D-4547-8907-A82C14DAAAE1Q54335658-265E24AC-152E-4D0C-8DDE-451BAB130E4DQ55495915-BD0AA689-006E-4622-B532-BD5BF40A0088Q57424151-928A1476-3625-4CDB-8E7C-F529E6777900
P2860
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A meta-analysis of randomized ...... metastatic colorectal cancer.
@ast
A meta-analysis of randomized ...... metastatic colorectal cancer.
@en
A meta-analysis of randomized ...... metastatic colorectal cancer.
@nl
type
label
A meta-analysis of randomized ...... metastatic colorectal cancer.
@ast
A meta-analysis of randomized ...... metastatic colorectal cancer.
@en
A meta-analysis of randomized ...... metastatic colorectal cancer.
@nl
prefLabel
A meta-analysis of randomized ...... metastatic colorectal cancer.
@ast
A meta-analysis of randomized ...... metastatic colorectal cancer.
@en
A meta-analysis of randomized ...... metastatic colorectal cancer.
@nl
P2093
P921
P1476
A meta-analysis of randomized ...... metastatic colorectal cancer.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00384-009-0655-9
P577
2009-01-30T00:00:00Z
P5875
P6179
1005226156